MAP3K7CL

Across TCGA pan-cancer cohorts, MAP3K7CL Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MAP3K7CL data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MAP3K7CL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP3K7CL expression acts as an unfavorable survival marker.

UCEC are the cancer types where MAP3K7CL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.282	0.604	.024	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

MAP3K7CL–UCEC (OS)

Open the UCEC breakdown →